KIR3DL1 and neuroblastoma: We have previously presented data that did not show improved outcome for patients with KIR-ligand-missing in specific studies for follicular lymphoma patients treated with maintenance rituximab, neuroblastoma patients treated with anti-GD2 dinutuximab, and metastatic renal cell carcinoma patients treated with HD-IL2 [9, 11, 34].